Fairvalue-Calculator Fairvalue-Calculator
EN DE

Zealand Pharma A/S, a biotechnology company, (ZLDPF) Fair Value & Analysis

Healthcare · US · Market cap $3.0B

Price$42.89
Fair Value$41.21
Upside-3.9%
Quality95/100
Evidence: High Range $33.11 – $125.55

Fair value as of: Jun 26, 2026

Analysis

Zealand Pharma A/S, a biotechnology company, (ZLDPF) currently trades at $42.89, while our model-based Fair Value estimate is $41.21 — implying the stock looks roughly 3.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Zealand Pharma A/S, a biotechnology company, (ZLDPF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $41.21 versus a price of $42.89 — about −4% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ZLDPF?
Our 21-model fair value for Zealand Pharma A/S, a biotechnology company, is $41.21 (as of Jun 26, 2026), built from audited fundamentals. The current price is $42.89.
What is the quality score of ZLDPF?
Zealand Pharma A/S, a biotechnology company, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.